30 filings
8-K
MLTX
MoonLake Immunotherapeutics - Ordinary Shares
7 May 24
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
8:01am
8-K
MLTX
MoonLake Immunotherapeutics - Ordinary Shares
11 Mar 24
Regulation FD Disclosure
8:01am
8-K
MLTX
MoonLake Immunotherapeutics - Ordinary Shares
29 Feb 24
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10
8:03am
8-K
MLTX
MoonLake Immunotherapeutics - Ordinary Shares
26 Feb 24
Regulation FD Disclosure
9:00am
8-K
MLTX
MoonLake Immunotherapeutics - Ordinary Shares
14 Nov 23
MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
12:00am
8-K
fit90s160h9g3ump8l2y
6 Nov 23
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
7:55am
8-K
gjsc kgdicugf4lg
16 Oct 23
Regulation FD Disclosure
6:16am
8-K
pj7sb 6dk6ejr6t
11 Sep 23
Regulation FD Disclosure
11:59am
8-K
mhwbg7m n2
1 Sep 23
Departure of Directors or Certain Officers
5:00pm
8-K
ifhww0a orcl8
10 Aug 23
MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update
8:15am
8-K
wwwa5m7a 1a0
29 Jun 23
Entry into a Material Definitive Agreement
4:13pm
8-K
fjab8ix
26 Jun 23
MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa
8:45am
8-K
k5q twbcipielnbd
7 Jun 23
Submission of Matters to a Vote of Security Holders
4:31pm
8-K
6raq67
19 May 23
Departure of Directors or Certain Officers
4:30pm
8-K
9a86m7q5 m1v
19 Apr 23
Regulation FD Disclosure
9:15am
8-K
gtq4bc
20 Mar 23
MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update
7:44am
8-K
063g4lp4ebniemw
10 Mar 23
Regulation FD Disclosure
5:07pm
8-K
gprqiew y4n
17 Jun 22
Changes in Registrant's Certifying Accountant
4:05pm
8-K
zdirega
7 Jun 22
Regulation FD Disclosure
8:31am
8-K/A
w7fw87pf5b02a 9pjh8
16 May 22
Completion of Acquisition or Disposition of Assets
4:10pm